English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Despite the long period of studying non-alcoholic fatty liver disease, its timely diagnosis, prevention and treatment remains one of the most pressing problems of medicine. However, the arsenal of effective and safe medicines used for this task is limited. The goal of this study was to elaborate a model of non-alcoholic fatty liver disease of varying severity in laboratory rats, and to analyze the influence of hepatoprotector medicine Remaxol upon the dynamics of biochemical parameters in experimental groups. The model of non-alcoholic fatty liver disease in laboratory rats permits to reproduce disease of va rying severity: semi–light severity of the disease (non-alcoholic hepatic steatosis) and average degree of severity (nonalcoholic steatohepatitis). The introduction of the test drug was carried out daily during 10 days of experiment starting from day 28th. Used model in experimental animals was characterized by the development of bilirubinemia, cholesterolemia (mainly due to triacylglycerides), activation of peroxidation, cytolytic and cholestatic syndromes. The severity of metabolic disturbances in the rats depended on the severity of the simulated disease. The analysis of the functional activity of the liver changes on the background of the application of Remaxol was performed for 11 parameters, yielding a complete picture of their condition. Distinct therapeutic effect of infusion of Remaxol on the model of liver steatosis (mild fatty liver) and in models of moderate severity (steatohepatitis), aimed at correcting observed violations was demonstrated in the study.

Biochemical profile of rats with non-alcoholic fatty liver disease of various gravity and its correction with Remaxol